|
시장보고서
상품코드
1523038
세계의 HER2 검사 시장 보고서 : 예측, 경쟁 분석(-2030년)HER2 Testing Market Report: Trends, Forecast and Competitive Analysis to 2030 |
||||||
Lucintel
HER2 검사 동향 및 예측
세계의 HER2 검사 시장은 2024년부터 2030년까지 복합 연간 성장률(CAGR) 7.1%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 맞춤형 의료 접근법의 중요성이 증가하고 유방암과 위암의 유병률이 급증하는 것입니다. 세계의 HER2 검사 시장의 미래는 병원과 진단 실험실 시장의 기회에 의해 유망시되고 있습니다.
부문별 HER2 검사
이 조사에는 세계의 HER2 검사 기술별, 암 유형별, 최종 용도별, 지역별 예측이 포함되어 있습니다.
HER2 검사 시장 인사이트
Lucintel은 형광 in situ 하이브리드 화(FISH)가 비용 효율적이고 신속한 납기로 예측 기간 동안 가장 큰 부문을 유지할 것으로 예측됩니다.
이 시장에서는 전문 의료기기와 인프라를 사용할 수 있기 때문에 병원이 가장 큰 부문으로 계속 될 것으로 보입니다.
북미는 유방암의 유병률이 높기 때문에 예측 기간 동안에도 최대의 지역으로 계속 될 것으로 보입니다.
FAQ
Q1. 시장 성장 예측은 :
A1. 세계의 HER2 검사 시장은 2024년부터 2030년까지 복합 연간 성장률(CAGR) 7.1%로 성장할 전망입니다.
Q2. 시장 성장에 영향을 미치는 주요 촉진요인은 :
A2. 이 시장의 주요 촉진요인은 개인화된 의료 접근의 중요성 증가와 유방암 및 위암의 유병률의 급증입니다.
Q3. 시장의 주요 부문은 :
A3. HER2 검사 시장의 미래는 병원 및 진단 실험실 시장에서 기회에 의해 유망할 것입니다.
Q4. 시장의 주요 기업은 :
A4. HER2 검사 주요 기업은 다음과 같습니다.
- Abbott
- Hoffmann-La Roche
- Agilent Technologies
- Thermo Fisher Scientific
- Leica Biosystems
- Empire Genomics
- Bio-Genex Laboratories
Q5. 앞으로 가장 큰 시장 부문은 :
A5. Lucintel은 형광 in situ 하이브리드 화(FISH)가 비용 효율적이고 납기가 빠르기 때문에 예측 기간 동안에도 최대 부문으로 계속 될 것으로 예측했습니다.
Q6. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은:
A6. 북미는 유방암의 유병률이 높기 때문에 예측기간 중에도 가장 규모가 큰 지역입니다.
Q7. 보고서 사용자 정의는 가능한가?
A7. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.
목차
제1장 주요 요약
제2장 세계의 HER2 검사 시장 : 시장 역학
- 소개, 배경, 분류
- 공급망
- 업계의 촉진요인과 과제
제3장 시장 동향과 예측 분석(2018년-2030년)
- 거시경제 동향(2018년-2023년)과 예측(2024년-2030년)
- 세계의 HER2 검사 시장 동향(2018년-2023년)과 예측(2024년-2030년)
- 기술별 HER2 검사 시장
- 형광 in situ 하이브리드화(FISH)
- 듀얼 프로브
- 싱글 프로브
- 발색 in situ 하이브리드화(CISH)
- 은 증감 in situ 하이브리드
- 암종별 HER2 검사 시장
- 유방암
- 위암
- 최종 용도별 HER2 검사 시장
- 병원
- 진단 실험실
- 기타
제4장 지역별 시장 동향과 예측 분석(2018년-2023년)
- 지역별 HER2 검사 시장
- 북미 HER2 검사 시장
- 유럽의 HER2 검사 시장
- 아시아태평양의 HER2 검사 시장
- 기타 지역의 HER2 검사 시장
제5장 경쟁 분석
- 제품 포트폴리오 분석
- 업무 통합
- Porter's Five Forces 분석
제6장 성장 기회와 전략 분석
- 성장 기회 분석
- 기술별 HER2 검사 시장에서의 성장 기회
- 암 유형별 세계의 HER2 검사 시장의 성장 기회
- 최종 용도별 세계의 HER2 검사 시장의 성장 기회
- 지역별 세계의 HER2 검사 시장의 성장 기회
- 세계의 HER2 검사 시장의 새로운 동향
- 전략 분석
- 신제품 개발
- 세계의 HER2 검사 시장의 능력 확대
- 세계의 HER2 검사 시장에서의 합병, 인수, 합작 사업
- 인증 및 라이선싱
제7장 주요 기업의 기업 프로파일
- Abbott
- Hoffmann-La Roche
- Agilent Technologies
- Thermo Fisher Scientific
- Leica Biosystems
- Empire Genomics
- Bio-Genex Laboratories
HER2 Testing Trends and Forecast
The future of the global HER2 testing market looks promising with opportunities in the hospitals and diagnostic laboratories markets. The global HER2 testing market is expected to grow with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are increasing significance of personalized medical approaches and surge in the prevalence of breast and gastric cancers.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
HER2 Testing by Segment
The study includes a forecast for the global HER2 testing by technique, cancer type, end use, and region.
HER2 Testing Market by Technique [Shipment Analysis by Value from 2018 to 2030]:
- Fluorescence In Situ Hybridization
- Dual-Probe
- Single-Probe
- Chromogenic In Situ Hybridization
- Silver-Enhanced In Situ Hybridization
HER2 Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:
- Breast Cancer
- Gastric Cancer
HER2 Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
- Hospitals
- Diagnostic Laboratories
- Others
HER2 Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of HER2 Testing Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies HER2 testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the HER2 testing companies profiled in this report include-
- Abbott
- Hoffmann-La Roche
- Agilent Technologies
- Thermo Fisher Scientific
- Leica Biosystems
- Empire Genomics
- Bio-Genex Laboratories
HER2 Testing Market Insights
Lucintel forecasts that fluorescence in situ hybridization will remain the largest segment over the forecast period due to their cost-effectiveness and faster turnaround times.
Within this market, hospitals will remain the largest segment due to availability of specialized medical equipment and infrastructure.
North America will remain the largest region over the forecast period due to high prevalence of breast cancer.
Features of the Global HER2 Testing Market
Market Size Estimates: HER2 testing market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: HER2 testing market size by technique, cancer type, end use, and region in terms of value ($B).
Regional Analysis: HER2 testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different techniques, cancer types, end uses, and regions for the HER2 testing market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the HER2 testing market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the growth forecast for HER2 testing market?
Answer: The global HER2 testing market is expected to grow with a CAGR of 7.1% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the HER2 testing market?
Answer: The major drivers for this market are increasing significance of personalized medical approaches and surge in the prevalence of breast and gastric cancers.
Q3. What are the major segments for HER2 testing market?
Answer: The future of the HER2 testing market looks promising with opportunities in the hospitals and diagnostic laboratories markets.
Q4. Who are the key HER2 testing market companies?
Answer: Some of the key HER2 testing companies are as follows:
- Abbott
- Hoffmann-La Roche
- Agilent Technologies
- Thermo Fisher Scientific
- Leica Biosystems
- Empire Genomics
- Bio-Genex Laboratories
Q5. Which HER2 testing market segment will be the largest in future?
Answer: Lucintel forecasts that fluorescence in situ hybridization will remain the largest segment over the forecast period due to their cost-effectiveness and faster turnaround times.
Q6. In HER2 testing market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to high prevalence of breast cancer.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the HER2 testing market by technique (fluorescence in situ hybridization, dual-probe, single-probe, chromogenic in situ hybridization, and silver-enhanced in situ hybridization), cancer type (breast cancer and gastric cancer), end use (hospitals, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Global HER2 Testing Market : Market Dynamics
- 2.1: Introduction, Background, and Classifications
- 2.2: Supply Chain
- 2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
- 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
- 3.2. Global HER2 Testing Market Trends (2018-2023) and Forecast (2024-2030)
- 3.3: Global HER2 Testing Market by Technique
- 3.3.1: Fluorescence in situ hybridization
- 3.3.2: Dual-probe
- 3.3.3: Single-probe
- 3.3.4: Chromogenic in situ hybridization
- 3.3.5: Silver-enhanced in situ hybridization
- 3.4: Global HER2 Testing Market by Cancer Type
- 3.4.1: Breast Cancer
- 3.4.2: Gastric Cancer
- 3.5: Global HER2 Testing Market by End Use
- 3.5.1: Hospitals
- 3.5.2: Diagnostic Laboratories
- 3.5.3: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
- 4.1: Global HER2 Testing Market by Region
- 4.2: North American HER2 Testing Market
- 4.2.1: North American HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
- 4.2.2: North American HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
- 4.3: European HER2 Testing Market
- 4.3.1: European HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
- 4.3.2: European HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
- 4.4: APAC HER2 Testing Market
- 4.4.1: APAC HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
- 4.4.2: APAC HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
- 4.5: ROW HER2 Testing Market
- 4.5.1: ROW HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
- 4.5.2: ROW HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
5. Competitor Analysis
- 5.1: Product Portfolio Analysis
- 5.2: Operational Integration
- 5.3: Porter's Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
- 6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global HER2 Testing Market by Technique
- 6.1.2: Growth Opportunities for the Global HER2 Testing Market by Cancer Type
- 6.1.3: Growth Opportunities for the Global HER2 Testing Market by End Use
- 6.1.4: Growth Opportunities for the Global HER2 Testing Market by Region
- 6.2: Emerging Trends in the Global HER2 Testing Market
- 6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global HER2 Testing Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global HER2 Testing Market
- 6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
- 7.1: Abbott
- 7.2: Hoffmann-La Roche
- 7.3: Agilent Technologies
- 7.4: Thermo Fisher Scientific
- 7.5: Leica Biosystems
- 7.6: Empire Genomics
- 7.7: Bio-Genex Laboratories
